Last updated: February 23, 2024
Sponsor: Children's National Research Institute
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Williams Syndrome
Asperger's Disorder
Treatment
Executive function group therapy
Clinical Study ID
NCT05131659
Pro00015492
1P50HD105328-01
Ages 14-18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 14-18 years of age inclusive
- Full scale IQ > 80 on a standardized IQ test, either confirmed through educationaltesting within the last two years or confirmed by the Wechsler Abbreviated Scale ofIntelligence (WASI-2) administered by research personnel. If current IQ testing (FSIQ)is not interpretable based on discrepancies between verbal and perceptual skills, wewill use the best available verbal IQ estimate.
- Broad ASD diagnosis according to Diagnostic Statistical Manual, fifth edition (DSM-5)criteria established by parent report of prior clinical diagnosis and confirmed bymeeting cutoff criteria on the Social Communication Questionnaire (i.e., raw score >
- or the Autism Diagnostic Observation Schedule-2 (ADOS-2), Module 4 (total score ≥7).
- Intact or corrected hearing and vision.
- Parents/guardians speak and read English with sufficient fluency for completion ofconsent forms and informant questionnaires; youth participants will use/understandEnglish as a primary or secondary language with sufficient fluency to engageeffectively in executive function group therapy conducted in English, and for validadministration of neuropsychological and behavioral measures.
Exclusion
Exclusion Criteria:
- Presence of a known medical condition in the participant that would interfere withhis/her ability to participate in the study.
- To preserve the integrity of the neuroimaging data, participants will be excluded ifthey have a history of neurological disorder, such as an established epilepsydiagnosis, significant brain trauma, hydrocephalus, central nervous system infection,or stroke.
- Contraindications for MRI such as metal implants, dental braces, pregnancy (determinedby parent or self-report).
Study Design
Total Participants: 64
Treatment Group(s): 1
Primary Treatment: Executive function group therapy
Phase:
Study Start date:
October 20, 2021
Estimated Completion Date:
May 31, 2026
Connect with a study center
Children's National Hospital
Washington, District of Columbia 20010
United StatesSite Not Available
Georgetown University
Washington, District of Columbia 20057
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.